Developments in immunotherapy
Developments in immunotherapy
Putting adoptive T cell therapy on the path to regulatory approval
Using Hsp90 inhibitors in the clinic: what have we learned?
Radiogenomic evaluation of tumour response to targeted agents
Mutant-specific kinase inhibitors and TAT highlights
New drugs and targets in haematological malignancies
Drugging the cancer genome to overcome drug resistance
ecancermedicalscience editor's choice for February 2015
Adjuvant treatment with sorafenib or sunitinib does not improve outcomes in localised renal carcinoma
Combination of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma
VEGF targeted therapy and chemo an active combination in rapidly progressive renal cell carcinoma
Impact of statins on survival outcomes in metastatic renal cell carcinoma